$ESPR
Esperion Therapeutics Inc

2019 Form 10-K Financial Statement

#000110465920026203 Filed on February 27, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018 Q3
Revenue $148.4M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $65.85M $11.20M $9.000M
YoY Change 98.97% 111.32% 57.89%
% of Gross Profit
Research & Development $175.6M $49.47M $41.55M
YoY Change 2.4% 48.12% 3.62%
% of Gross Profit
Depreciation & Amortization $300.0K $80.00K $70.00K
YoY Change 0.0% 33.33% 0.0%
% of Gross Profit
Operating Expenses $241.5M $60.65M $50.56M
YoY Change 18.03% 56.72% 10.64%
Operating Profit -$93.10M -$60.65M -$50.56M
YoY Change -54.49%
Interest Expense $8.120M $0.00 $600.0K
YoY Change 28900.0%
% of Operating Profit
Other Income/Expense, Net $4.056M $600.0K $651.0K
YoY Change 44.7% -25.0% 8.5%
Pretax Income -$97.20M -$60.00M -$49.90M
YoY Change -51.83% 58.31% 10.4%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$97.17M -$60.04M -$49.91M
YoY Change -51.85% 58.41% 10.42%
Net Earnings / Revenue -65.49%
Basic Earnings Per Share -$3.59
Diluted Earnings Per Share -$3.59 -$2.239M -$1.862M
COMMON SHARES
Basic Shares Outstanding 27.09M shares
Diluted Shares Outstanding 27.09M shares

Balance Sheet

Concept 2019 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $200.8M $136.0M $159.2M
YoY Change 47.65% -32.06% -21.73%
Cash & Equivalents $166.1M $36.97M $26.76M
Short-Term Investments $34.70M $99.05M $132.5M
Other Short-Term Assets $10.90M $6.600M $9.000M
YoY Change 65.15% 78.38% 157.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $211.7M $142.6M $168.2M
YoY Change 48.46% -30.05% -18.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.700M $520.0K $600.0K
YoY Change 440.0% 30.0% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $200.0K $5.200M
YoY Change -99.73% -95.08%
Other Assets
YoY Change
Total Long-Term Assets $2.700M $819.0K $5.800M
YoY Change 200.0% -98.89% -94.54%
TOTAL ASSETS
Total Short-Term Assets $211.7M $142.6M $168.2M
Total Long-Term Assets $2.700M $819.0K $5.800M
Total Assets $214.4M $143.5M $174.0M
YoY Change 49.41% -48.36% -44.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $28.90M $44.89M $18.60M
YoY Change -35.63% 120.06% -4.62%
Accrued Expenses $29.80M $19.40M $23.70M
YoY Change 53.61% 65.81% 69.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $66.10M $64.33M $42.30M
YoY Change 2.8% 94.36% 20.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $128.4M
YoY Change
Total Long-Term Liabilities $128.4M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $66.10M $64.33M $42.30M
Total Long-Term Liabilities $128.4M $0.00 $0.00
Total Liabilities $194.5M $64.33M $42.30M
YoY Change 202.49% 94.36% 20.86%
SHAREHOLDERS EQUITY
Retained Earnings -$598.1M
YoY Change
Common Stock $27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.00M $79.12M $131.7M
YoY Change
Total Liabilities & Shareholders Equity $214.4M $143.5M $174.0M
YoY Change 49.41% -48.36% -44.43%

Cashflow Statement

Concept 2019 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$97.17M -$60.04M -$49.91M
YoY Change -51.85% 58.41% 10.42%
Depreciation, Depletion And Amortization $300.0K $80.00K $70.00K
YoY Change 0.0% 33.33% 0.0%
Cash From Operating Activities -$70.34M -$28.69M -$37.53M
YoY Change -52.68% -17.72% 4.57%
INVESTING ACTIVITIES
Capital Expenditures $953.0K -$100.0K -$50.00K
YoY Change 531.13%
Acquisitions
YoY Change
Other Investing Activities $65.18M $38.67M $40.08M
YoY Change -53.64% -20.1% -131.43%
Cash From Investing Activities $64.23M $38.57M $40.03M
YoY Change -54.27% -20.31% -131.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities $136.2M 340.0K -130.0K
YoY Change 1173.56% -525.0% -100.08%
NET CHANGE
Cash From Operating Activities -$70.34M -28.69M -37.53M
Cash From Investing Activities $64.23M 38.57M 40.03M
Cash From Financing Activities $136.2M 340.0K -130.0K
Net Change In Cash $130.1M 10.22M 2.370M
YoY Change 5093.01% -24.01% 264.62%
FREE CASH FLOW
Cash From Operating Activities -$70.34M -$28.69M -$37.53M
Capital Expenditures $953.0K -$100.0K -$50.00K
Free Cash Flow -$71.29M -$28.59M -$37.48M
YoY Change -52.08% -18.01% 4.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27497911
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26824859
CY2018 espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
CY2019 espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001434868
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-35986
CY2019 dei Entity Registrant Name
EntityRegistrantName
Esperion Therapeutics, Inc.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1870780
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
3891 Ranchero Drive, Suite 150
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2019 dei City Area Code
CityAreaCode
734
CY2019 dei Local Phone Number
LocalPhoneNumber
887-3903
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Trading Symbol
TradingSymbol
ESPR
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
1090000000.00
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27512441
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166130000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36973000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
928000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34651000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99050000
CY2019Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
6081000
CY2018Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
5275000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3924000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1334000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
211714000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
142632000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1145000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
520000
CY2019Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
56000
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
56000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
243000
CY2019Q4 espr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
1532000
CY2019Q4 us-gaap Assets
Assets
214447000
CY2018Q4 us-gaap Assets
Assets
143451000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28856000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44893000
CY2019Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
17511000
CY2018Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
16039000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11871000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3401000
CY2019Q4 espr Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
5236000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2152000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
454000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66080000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64333000
CY2019Q4 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
127308000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1109000
CY2019Q4 us-gaap Liabilities
Liabilities
194497000
CY2018Q4 us-gaap Liabilities
Liabilities
64333000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-319000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27497911
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26824859
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
715166000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
677511000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
65854000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
171488000
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
147603000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695266000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-598101000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19950000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
79118000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214447000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143451000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148364000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148364000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
175611000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33097000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21379000
CY2019 us-gaap Operating Expenses
OperatingExpenses
241465000
CY2018 us-gaap Operating Expenses
OperatingExpenses
204585000
CY2017 us-gaap Operating Expenses
OperatingExpenses
168982000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-93101000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-204585000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-168982000
CY2019 us-gaap Interest Expense
InterestExpense
8120000
CY2018 us-gaap Interest Expense
InterestExpense
28000
CY2017 us-gaap Interest Expense
InterestExpense
198000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4056000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2803000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2192000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-97165000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-201810000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-166988000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.59
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.54
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.98
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27090284
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26754308
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23933273
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
342000
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
526000
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-673000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96823000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-201284000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-167661000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
228602000
CY2017 espr Payments Of Stock Issuance Costs And Deferred Offering Costs Incurred
PaymentsOfStockIssuanceCostsAndDeferredOfferingCostsIncurred
226000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
163978000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1167000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18605000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-673000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-166988000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
244691000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11743000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23968000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
526000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-201810000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
79118000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11771000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25884000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
342000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-97165000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19950000
CY2019 us-gaap Profit Loss
ProfitLoss
-97165000
CY2018 us-gaap Profit Loss
ProfitLoss
-201810000
CY2017 us-gaap Profit Loss
ProfitLoss
-166988000
CY2019 us-gaap Depreciation
Depreciation
319000
CY2018 us-gaap Depreciation
Depreciation
265000
CY2017 us-gaap Depreciation
Depreciation
258000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
200000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
217000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-334000
CY2019 espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
8120000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
25884000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
23968000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
18605000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3396000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2884000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1731000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2152000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16055000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24446000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15758000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
10000000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
7594000
CY2017 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2462000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70341000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148638000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131302000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34326000
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25481000
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
219577000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
99510000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
166081000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
183743000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
953000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
151000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64231000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
140449000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35853000
CY2017 espr Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
164000000
CY2019 espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
124424000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10694000
CY2019Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
538000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11771000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11743000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1167000
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1049000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1709000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
136195000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163458000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
130085000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2505000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3697000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34468000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38165000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167058000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34468000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
190000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
CY2019 espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
31000
CY2017 espr Deferred Offering Costs Incurred
DeferredOfferingCostsIncurred
22000
CY2019Q3 espr Number Of Patients Enrolled In Global Cardiovascular Outcomes Trial
NumberOfPatientsEnrolledInGlobalCardiovascularOutcomesTrial
14032
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. Actual results could differ from those estimates.</span></p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to concentrations of credit risk. The Company has established guidelines for investment of its excess cash and believes the guidelines maintain safety and liquidity through diversification of counterparties and maturities.</p>
CY2019Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
987000
CY2019Q4 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
216000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
292500000
CY2019Q4 espr Revenue Interest Liability Payments Due After Year Five
RevenueInterestLiabilityPaymentsDueAfterYearFive
292500000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1741000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
538000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148400000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148400000
CY2019Q4 espr Revenue Interest Liability Payments Due Total
RevenueInterestLiabilityPaymentsDueTotal
292500000
CY2019Q4 espr Lessee Operating Lease Liability Payments Due Years Two And Three
LesseeOperatingLeaseLiabilityPaymentsDueYearsTwoAndThree
987000
CY2019Q4 espr Lessee Operating Lease Liability Payments Due Years Four And Five
LesseeOperatingLeaseLiabilityPaymentsDueYearsFourAndFive
216000
CY2019Q4 us-gaap Contractual Obligation
ContractualObligation
294241000
CY2019Q4 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
62589000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2176000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1516000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1031000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
996000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1145000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
520000
CY2019 us-gaap Depreciation
Depreciation
300000
CY2018 us-gaap Depreciation
Depreciation
300000
CY2017 us-gaap Depreciation
Depreciation
300000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7818000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1833000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3842000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1228000
CY2019Q4 espr Accrued Franchise And Property Taxes Current
AccruedFranchiseAndPropertyTaxesCurrent
37000
CY2018Q4 espr Accrued Franchise And Property Taxes Current
AccruedFranchiseAndPropertyTaxesCurrent
44000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
174000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
296000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11871000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3401000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
23000
CY2019Q4 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
62612000
CY2018Q4 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
134138000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
319000
CY2018Q4 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
133819000
CY2018 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
CY2019 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5303723
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.01
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
83473000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
542875
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
46.95
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
519140
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
50.24
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
649529
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.12
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4677929
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.31
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M25D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109054000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4677929
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
39.31
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M25D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
109054000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2993362
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.24
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M2D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
86698000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
17700000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12100000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000000.0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0210
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0204
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M15D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M8D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.72
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
31.18
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.56
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.99
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
48600000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
538000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
517000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
470000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
216000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1741000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
178000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1563000
CY2019Q4 espr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
1532000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1532000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
454000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1109000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1563000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Existing Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetExistingIncomeTaxExpense
50400000
CY2017 us-gaap Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Existing Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateExistingIncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
174200000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
152200000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
99800000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.002
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.296
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.005
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.009
CY2019 espr Effective Income Tax Rate Reconciliation Amended Tax Returns
EffectiveIncomeTaxRateReconciliationAmendedTaxReturns
0.000
CY2018 espr Effective Income Tax Rate Reconciliation Amended Tax Returns
EffectiveIncomeTaxRateReconciliationAmendedTaxReturns
0.000
CY2017 espr Effective Income Tax Rate Reconciliation Amended Tax Returns
EffectiveIncomeTaxRateReconciliationAmendedTaxReturns
0.045
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.215
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.097
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
450000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1077000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1387000
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1142000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
154912000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
138299000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17217000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13542000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2089000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
341000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
174218000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
152182000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
174218000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
152182000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4923895
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5349428
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4354507
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166130000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36973000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
928000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167058000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145419000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
982000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
981000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
982000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145419000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
982000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
981000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
982000
CY2019Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
46308000
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42788000
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48281000
CY2019Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38234000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12182000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13492000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18468000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21712000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
58490000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
56280000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
66749000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
59946000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
86929000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55298000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65768000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-58964000
CY2019Q3 us-gaap Interest Expense
InterestExpense
3996000
CY2019Q4 us-gaap Interest Expense
InterestExpense
4124000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
87379000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54221000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-68377000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-61946000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.26
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.07
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.01
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26605189
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26786796
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26804026
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26818331
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.26
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.52
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.52
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.26
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26842785
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26968818
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27171769
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27371067
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28449767
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26968818
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27171769
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27371067
CY2018Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40940000
CY2018Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
39524000
CY2018Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
41551000
CY2018Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
49473000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5954000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6956000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9011000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11176000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
46894000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
46480000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
50562000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
60649000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46894000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-46480000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50562000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-60649000
CY2018Q1 espr Other Nonoperating Income Expense Net Of Interest Expense
OtherNonoperatingIncomeExpenseNetOfInterestExpense
764000
CY2018Q2 espr Other Nonoperating Income Expense Net Of Interest Expense
OtherNonoperatingIncomeExpenseNetOfInterestExpense
750000
CY2018Q3 espr Other Nonoperating Income Expense Net Of Interest Expense
OtherNonoperatingIncomeExpenseNetOfInterestExpense
651000
CY2018Q4 espr Other Nonoperating Income Expense Net Of Interest Expense
OtherNonoperatingIncomeExpenseNetOfInterestExpense
610000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-46130000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-45730000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-49911000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-60039000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.86
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.24

Files In Submission

Name View Source Status
0001104659-20-026203-index-headers.html Edgar Link pending
0001104659-20-026203-index.html Edgar Link pending
0001104659-20-026203.txt Edgar Link pending
0001104659-20-026203-xbrl.zip Edgar Link pending
espr-20191231.xsd Edgar Link pending
espr-20191231x10k209bec.htm Edgar Link pending
espr-20191231x10k209bec001.jpg Edgar Link pending
espr-20191231x10k209bec_htm.xml Edgar Link completed
espr-20191231_cal.xml Edgar Link unprocessable
espr-20191231_def.xml Edgar Link unprocessable
espr-20191231_lab.xml Edgar Link unprocessable
espr-20191231_pre.xml Edgar Link unprocessable
ex-10d16.htm Edgar Link pending
ex-23d1.htm Edgar Link pending
ex-31d1.htm Edgar Link pending
ex-31d2.htm Edgar Link pending
ex-32d1.htm Edgar Link pending
ex-4d4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending